Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg, 30-count bottle, Rx only, Mfd. for: Arbor Pharmaceuticals, LLC., Atlanta, Georgia, 30328, NDC 24338-856-03

Labeling: Label Mix-up

Recall #: D-0323-2024
Affected scope: 4,662 bottles
Initiated: January 4, 2024

Compiled from official public sources by the publisher. · Updated September 2026

Azurity Pharmaceuticals, Inc. recalled Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg, 30-count bottle, Rx only, Mf… - a critical-severity action.

Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg, 30-count bottle, Rx only, Mf… was recalled by Azurity Pharmaceuticals, Inc. in February 7, 2024. Reason: Labeling: Label Mix-up. Check the official notice for the remedy. Verify recall #D-0323-2024 with the FDA Drug before acting.

The recall

Azurity Pharmaceuticals, Inc. issued this critical-severity FDA Drug recall-Labeling: Label Mix-up.

Critical
severity level: Class I
classification: February 7, 2024
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0323-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 1 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified high severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg, 30-count bottle, Rx only, Mfd. for: Arbor Pharmaceuticals, LLC., Atlanta, Georgia, 30328, NDC 24338-856-03

Reason for recall

Labeling: Label Mix-up

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Critical (Class I)
Status	Terminated
Recall number	D-0323-2024
Date reported	February 7, 2024
Date initiated	January 4, 2024
Recalling firm	Azurity Pharmaceuticals, Inc.
Firm location	Wilmington, MA
Affected scope	4,662 bottles
Distribution	USA nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0323-2024) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
This is a Class I (high-risk) recall, stop using the product immediately and follow the disposal or return instructions. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg, 30-count bottle, Rx only, Mfd. for: Arbor Pharmaceuticals, LLC., Atlanta, Georgia, 30328, NDC 24338-856-03. Recalled by Azurity Pharmaceuticals, Inc.. Units affected: 4,662 bottles.

Why was this product recalled? ▼

Labeling: Label Mix-up

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on February 7, 2024. Severity: Critical. Recall number: D-0323-2024.

Where was the recalled product distributed? ▼

Distribution: USA nationwide.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Critical), closest by report date among other firms and states.

LUCID 2022-2024: FORWARD COLLISION AVOIDA… 2024-02-07 KIA 2024: ENGINE AND ENGINE COOLING:ENGIN… 2024-02-07 FentaNYL citrate PF, 1000 mcg per 100 mL … 2024-02-07 FentaNYL citrate PF, 2500 mcg per 250 mL … 2024-02-07

Similar Children & Baby Products · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Cefixime for Oral Suspension 100mg/5mL, 5… 2024-02-07 Budesonide Extended-Release Tablets 9mg, … 2024-02-07 Hydrogen Peroxide Oral Rinse, Significant… 2024-02-07 Solgar, Triple Strength, Shellfish -Free,… 2024-02-07

Compare this recall with CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per … → · All Children & Baby Products recalls

This recall: FDA Drug, reported February 7, 2024. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026